XML 116 R97.htm IDEA: XBRL DOCUMENT v3.22.4

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Accounting Policies [Abstract]

Schedule of cash and cash equivalents

The following represents a reconciliation of cash and cash equivalents in the condensed consolidated balance sheets to total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows as of September 30, 2022 and December 31, 2021 (in thousands).

			As of
			September 30, 2022						December 31, 2021
Cash and cash equivalents			$	50,370					$	128,318
Restricted cash (presented within Other current assets)			664						414
Cash, cash equivalents and restricted cash			$	51,034					$	128,732

The following represents a reconciliation of cash and cash equivalents in

the consolidated balance sheets to total cash, cash equivalents and restricted cash in the consolidated statement of cash flows as of December 31, 2021 and December 31, 2020.

			Year Ended December 31,
			2021						2020
Cash and cash equivalents			$	128,318					$	60,495
Restricted cash (presented within Other current assets)			414						414
Cash, cash equivalents and restricted cash			$	128,732					$	60,909

Customer concentration risk

Customers representing 10% or greater of revenue were as follows for the nine months ended September 30, 2022 and 2021:

			Nine months ended September 30,
			2022						2021
Customer A			24		%				16		%
Customer B			10		%				—		%
Customer C			10		%				3		%
Customer D			8		%				34		%
Customer E			8		%				12		%

Customers representing 10% or greater of revenue were as follows for the years ended December 31, 2021 and 2020:

			Year Ended December 31,
			2021						2020
			as Restated						as Restated
Customer A			27		%				28		%
Customer B			15		%				27		%
Customer C			12		%				22		%

Schedule of error corrections

The effects of the correction of these errors on the relevant financial statement line items is as follows:

			Year Ended December 31, 2021
			As Previously Reported						Adjustments						as Restated
Consolidated Balance Sheet
Equity method investments			26,479						(1,727)						24,752
Total assets			$	194,738					$	(1,727)					$	193,011
Accumulated deficit			(378,162)						(1,727)						(379,889)
Total shareholders’ deficit			$	(353,190)					$	(1,727)					$	(354,917)
Total liabilities, contingently redeemable preferred equity, and shareholders' deficit			$	194,738					$	(1,727)					$	193,011

			Year Ended December 31, 2020
			As Previously Reported						Adjustments						as Restated
Consolidated Balance Sheet
Contract assets			6,064						122						6,186
Total current assets			76,467						122						76,589
Equity method investments			24,023						(806)						23,217
Total assets			$	119,664					$	(684)					$	118,980
Other accrued liabilities			2,775						122						2,897
Total current liabilities			$	15,082					$	122					$	15,204
Total liabilities			$	35,666					$	122					$	35,788
Accumulated deficit			(332,394)						(806)						(333,200)
Total shareholders’ deficit			$	(310,410)					$	(806)					$	(311,216)
Total liabilities, contingently redeemable preferred equity, and shareholders' deficit			$	119,664					$	(684)					$	118,980

			Year Ended December 31, 2021
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Operations and Comprehensive Loss
Revenue from contracts with customers			18,993						(122)						18,871
Revenue from related party transactions			3,915						(662)						3,253
Total revenue			$	26,245					$	(784)					$	25,461
Cost of revenue from contracts with customers (exclusive of depreciation shown below)			(13,289)						122						(13,167)
Total cost and operating expenses			$	(76,602)					$	122					$	(76,480)
Loss from operations			$	(50,357)					$	(662)					$	(51,019)
Loss before income taxes			$	(47,972)					$	(662)					$	(48,634)
Gain from equity method investees, net			2,204						(259)						1,945
Net loss			$	(45,768)					$	(921)					$	(46,689)
Net loss allocated to common shareholders			$	(82,526)					$	(921)					$	(83,447)
Comprehensive loss			$	(45,673)					$	(921)					$	(46,594)
Net loss per share - basic and diluted			$	(42.12)					$	(0.47)					$	(42.59)

			Year Ended December 31, 2020
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Operations and Comprehensive Loss
Revenue from contracts with customers			12,865						122						12,987
Revenue from related party transactions			4,752						(549)						4,203
Total revenue			$	18,780					$	(427)					$	18,353
Cost of revenue from contracts with customers (exclusive of depreciation shown below)			(8,063)						(122)						(8,185)
Total cost and operating expenses			$	(57,932)					$	(122)					$	(58,054)
Loss from operations			$	(39,152)					$	(549)					$	(39,701)
Loss before income taxes			$	(39,331)					$	(549)					$	(39,880)
Gain from equity method investees, net			2,424						(257)						2,167
Net loss			$	(36,907)					$	(806)					$	(37,713)
Net loss allocated to common shareholders			$	(68,198)					$	(806)					$	(69,004)
Comprehensive loss			$	(36,282)					$	(806)					$	(37,088)
Net loss per share - basic and diluted			$	(41.84)					$	(0.50)					$	(42.34)

			Year Ended December 31, 2021
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity (Deficit)
Accumulated deficit - Balance at December 31, 2020			$	(332,394)					$	(806)					$	(333,200)
Total shareholders’ deficit – balance at December 31, 2020			$	(310,410)					$	(806)					$	(311,216)
Net loss			(45,768)						(921)						(46,689)
Accumulated deficit - balance at December 31, 2021			(378,162)						(1,727)						(379,889)
Total shareholders’ deficit – balance at December 31, 2021			$	(353,190)					$	(1,727)					$	(354,917)

			Year ended December 31, 2020
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Changes in Redeemable Convertible Preferred Stock and Shareholders’ Equity (Deficit)
Accumulated deficit - Balance at December 31, 2019			$	(295,487)					$	—					$	(295,487)
Total shareholders’ deficit – balance at December 31, 2019			$	(276,592)					$	—					$	(276,592)
Net loss			(36,907)						(806)						(37,713)
Accumulated deficit - balance at December 31, 2020			(332,394)						(806)						(333,200)
Total shareholders’ deficit – balance at December 31, 2020			$	(310,410)					$	(806)					$	(311,216)

			Year Ended December 31, 2021
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Cash Flows
Net loss			$	(45,768)					$	(921)					$	(46,689)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash recognition of licensing revenue			(2,684)						662						$	(2,022)
Gain from equity method investees, net			(2,204)						259						$	(1,945)
Changes in operating assets and liabilities:
Contract assets			(5,636)						122						(5,514)
Accounts payable and accrued salaries and wages			1,378						(122)						1,256
Net cash used in operating activities			$	(42,591)					$	—					$	(42,591)

			Year Ended December 31, 2020
			As Previously Reported						Adjustments						as Restated
Consolidated Statement of Cash Flows
Net loss			$	(36,907)					$	(806)					$	(37,713)
Adjustments to reconcile net loss to net cash used in operating activities:
Non-cash recognition of licensing revenue			(1,567)						549						$	(1,018)
Gain from equity method investees, net			(2,424)						257						$	(2,167)
Changes in operating assets and liabilities:
Contract assets			(5,483)						(122)						(5,605)
Accounts payable and accrued salaries and wages			568						122						690
Net cash used in operating activities			$	(39,271)					$	—					$	(39,271)

			Year Ended December 31, 2021
			As Previously Reported						as Restated
Gain on dilution			$	181					$	503

X

- References

No definition available.

+ Details

Name:	us-gaap_AccountingPoliciesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the components of cash and cash equivalents.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

+ Details

Name:	us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-URI https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration